UK Gives Historic Nod to Gene Editing Tool for Blood Disorders, High Costs & Long Wait May Limit Indians’ Access

The treatment for sickle cell disease and beta-thalassemia is the first to be licensed using the gene-editing tool Crispr, which earned its discoverers the Nobel Prize in 2020